Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082189666> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2082189666 endingPage "65" @default.
- W2082189666 startingPage "65" @default.
- W2082189666 abstract "In this prospective study, patients with ‘high risk’ primary MDS, namely RAEB or RAEBt, were treated with combination chemotherapy (CT) supported by GM-CSF. The induction CT consisted of idarubicin 6 mg/m2 days 1–3 and cytosine-arabinoside 200 mg/m2 in 12 h infusion, days 1–5. The GM-CSF 3 μg/kg s.c. was given on day 6 until the neutrophil count was 1 × 109/l. Postremission CT consisted of two similar courses. Patients not in remission after two courses of CT were considered as treatment failures. Twenty-two patients with a median age of 64 years, range 50–79 years (11 RAEB and 11 RAEBt) were evaluable. Twelve out of 22 patients (54.5%) achieved complete remission (CR) and four, partial remission. Six patients were resistant to treatment; there were two toxic deaths; seven patients achieved CR after the first course and five after two courses. The median time of neutrophil recovery to 1 × 109/l was day 15 (range 3–22) after the first course of treatment and day 14 (range 4–21) after the second. Thirteen out of 22 patients developed febrile episodes after the first course of treatment and nine after the second. The median duration of CR was 12 months. The median survival for CR patients was 24 months, for non-CR patients, 12 months; while survival for the whole population was 18 months.In conclusion, the results of this study indicate that the administration of moderately intensive CT supported by GM-CSF in ‘poor risk’ MDS gives promising results; the response rate is high for this disease, while the incidence of toxic death is low. GM-CSF appears to accelerate neutrophil recovery and probably reduces the incidence of infection." @default.
- W2082189666 created "2016-06-24" @default.
- W2082189666 creator A5017814449 @default.
- W2082189666 creator A5028336640 @default.
- W2082189666 creator A5033058488 @default.
- W2082189666 creator A5039891403 @default.
- W2082189666 creator A5039935199 @default.
- W2082189666 creator A5045043807 @default.
- W2082189666 creator A5056284792 @default.
- W2082189666 creator A5073264362 @default.
- W2082189666 creator A5076766644 @default.
- W2082189666 creator A5089892914 @default.
- W2082189666 date "1994-01-01" @default.
- W2082189666 modified "2023-10-14" @default.
- W2082189666 title "Intensive chemotherapy with or without G-CSF in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: Randomized clinical study" @default.
- W2082189666 doi "https://doi.org/10.1016/0145-2126(94)90252-6" @default.
- W2082189666 hasPublicationYear "1994" @default.
- W2082189666 type Work @default.
- W2082189666 sameAs 2082189666 @default.
- W2082189666 citedByCount "2" @default.
- W2082189666 crossrefType "journal-article" @default.
- W2082189666 hasAuthorship W2082189666A5017814449 @default.
- W2082189666 hasAuthorship W2082189666A5028336640 @default.
- W2082189666 hasAuthorship W2082189666A5033058488 @default.
- W2082189666 hasAuthorship W2082189666A5039891403 @default.
- W2082189666 hasAuthorship W2082189666A5039935199 @default.
- W2082189666 hasAuthorship W2082189666A5045043807 @default.
- W2082189666 hasAuthorship W2082189666A5056284792 @default.
- W2082189666 hasAuthorship W2082189666A5073264362 @default.
- W2082189666 hasAuthorship W2082189666A5076766644 @default.
- W2082189666 hasAuthorship W2082189666A5089892914 @default.
- W2082189666 hasConcept C126322002 @default.
- W2082189666 hasConcept C141071460 @default.
- W2082189666 hasConcept C2776694085 @default.
- W2082189666 hasConcept C2778041864 @default.
- W2082189666 hasConcept C2779117419 @default.
- W2082189666 hasConcept C2780007613 @default.
- W2082189666 hasConcept C2780817109 @default.
- W2082189666 hasConcept C3018657049 @default.
- W2082189666 hasConcept C71924100 @default.
- W2082189666 hasConcept C90924648 @default.
- W2082189666 hasConceptScore W2082189666C126322002 @default.
- W2082189666 hasConceptScore W2082189666C141071460 @default.
- W2082189666 hasConceptScore W2082189666C2776694085 @default.
- W2082189666 hasConceptScore W2082189666C2778041864 @default.
- W2082189666 hasConceptScore W2082189666C2779117419 @default.
- W2082189666 hasConceptScore W2082189666C2780007613 @default.
- W2082189666 hasConceptScore W2082189666C2780817109 @default.
- W2082189666 hasConceptScore W2082189666C3018657049 @default.
- W2082189666 hasConceptScore W2082189666C71924100 @default.
- W2082189666 hasConceptScore W2082189666C90924648 @default.
- W2082189666 hasLocation W20821896661 @default.
- W2082189666 hasOpenAccess W2082189666 @default.
- W2082189666 hasPrimaryLocation W20821896661 @default.
- W2082189666 hasRelatedWork W1987203832 @default.
- W2082189666 hasRelatedWork W2002493774 @default.
- W2082189666 hasRelatedWork W2061078414 @default.
- W2082189666 hasRelatedWork W3000533182 @default.
- W2082189666 hasRelatedWork W3031777054 @default.
- W2082189666 hasRelatedWork W3095832906 @default.
- W2082189666 hasRelatedWork W3195865374 @default.
- W2082189666 hasRelatedWork W4247120321 @default.
- W2082189666 hasRelatedWork W4253658883 @default.
- W2082189666 hasRelatedWork W4256458106 @default.
- W2082189666 hasVolume "18" @default.
- W2082189666 isParatext "false" @default.
- W2082189666 isRetracted "false" @default.
- W2082189666 magId "2082189666" @default.
- W2082189666 workType "article" @default.